139 related articles for article (PubMed ID: 27822421)
1. Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
Yan X; Liu L; Li H; Huang L; Yin M; Pan C; Qin H; Jin Z
Am J Cancer Res; 2016; 6(10):2323-2333. PubMed ID: 27822421
[TBL] [Abstract][Full Text] [Related]
2. High expression of Zinc-finger protein X-linked promotes tumor growth and predicts a poor outcome for stage II/III colorectal cancer patients.
Yan X; Shan Z; Yan L; Zhu Q; Liu L; Xu B; Liu S; Jin Z; Gao Y
Oncotarget; 2016 Apr; 7(15):19680-92. PubMed ID: 26967242
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of dual-specificity phosphatase 5 predicts poor prognosis of patients with prostate cancer.
Cai C; Chen JY; Han ZD; He HC; Chen JH; Chen YR; Yang SB; Wu YD; Zeng YR; Zou J; Liang YX; Dai QS; Jiang FN; Zhong WD
Int J Clin Exp Med; 2015; 8(3):4186-94. PubMed ID: 26064329
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Tbx3 is correlated with Epithelial-Mesenchymal Transition phenotype and predicts poor prognosis of colorectal cancer.
Shan ZZ; Yan XB; Yan LL; Tian Y; Meng QC; Qiu WW; Zhang Z; Jin ZM
Am J Cancer Res; 2015; 5(1):344-53. PubMed ID: 25628943
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of
Yan X; Liu L; Li H; Qin H; Sun Z
Onco Targets Ther; 2017; 10():5031-5046. PubMed ID: 29081665
[TBL] [Abstract][Full Text] [Related]
6.
Cheng C; Huang Z; Zhou R; An H; Cao G; Ye J; Huang C; Wu D
Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G841-G853. PubMed ID: 32146835
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of dual specificity phosphatase 22 in colorectal cancer and its potential prognostic relevance for stage IV CRC patients.
Yu D; Li Z; Gan M; Zhang H; Yin X; Tang S; Wan L; Tian Y; Zhang S; Zhu Y; Lai M; Zhang D
Tumour Biol; 2015 Nov; 36(11):8531-5. PubMed ID: 26032091
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer.
Toiyama Y; Yasuda H; Saigusa S; Tanaka K; Inoue Y; Goel A; Kusunoki M
Carcinogenesis; 2013 Nov; 34(11):2548-57. PubMed ID: 24001454
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum DAND5 is associated with metastasis and predicts poor prognosis in colorectal cancer.
Miao X; Zhang Y; Sun J; Cui S; Meng Q; Zhu K; Hu X; Wang T
United European Gastroenterol J; 2017 Aug; 5(5):725-734. PubMed ID: 28815037
[TBL] [Abstract][Full Text] [Related]
10. N-cadherin, a novel prognostic biomarker, drives malignant progression of colorectal cancer.
Yan X; Yan L; Liu S; Shan Z; Tian Y; Jin Z
Mol Med Rep; 2015 Aug; 12(2):2999-3006. PubMed ID: 25936636
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer.
Ge XC; Wu F; Li WT; Zhu XJ; Liu JW; Wang BL
Oncol Lett; 2017 Jun; 13(6):4341-4348. PubMed ID: 28599436
[TBL] [Abstract][Full Text] [Related]
12. Upregulated NNT-AS1, a long noncoding RNA, contributes to proliferation and migration of colorectal cancer cells in vitro and in vivo.
Wang Q; Yang L; Hu X; Jiang Y; Hu Y; Liu Z; Liu J; Wen T; Ma Y; An G; Feng G
Oncotarget; 2017 Jan; 8(2):3441-3453. PubMed ID: 27966450
[TBL] [Abstract][Full Text] [Related]
13. MiR-381 functions as a tumor suppressor in colorectal cancer by targeting Twist1.
He X; Wei Y; Wang Y; Liu L; Wang W; Li N
Onco Targets Ther; 2016; 9():1231-9. PubMed ID: 27094913
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-302c represses epithelial-mesenchymal transition and metastasis by targeting transcription factor AP-4 in colorectal cancer.
Ma W; Liu B; Li J; Jiang J; Zhou R; Huang L; Li X; He X; Zhou Q
Biomed Pharmacother; 2018 Sep; 105():670-676. PubMed ID: 29906744
[TBL] [Abstract][Full Text] [Related]
16. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
[TBL] [Abstract][Full Text] [Related]
17. LASP2 suppresses colorectal cancer progression through JNK/p38 MAPK pathway meditated epithelial-mesenchymal transition.
Wang B; Zhang L; Zhao L; Zhou R; Ding Y; Li G; Zhao L
Cell Commun Signal; 2017 Jun; 15(1):21. PubMed ID: 28606091
[TBL] [Abstract][Full Text] [Related]
18. BAF53A drives colorectal cancer development by regulating DUSP5-mediated ERK phosphorylation.
Yang Z; Huang D; Meng M; Wang W; Feng J; Fang L; Chen H; Zou S
Cell Death Dis; 2022 Dec; 13(12):1049. PubMed ID: 36526622
[TBL] [Abstract][Full Text] [Related]
19. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
[TBL] [Abstract][Full Text] [Related]
20. High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer.
Yan X; Yan L; Zhou J; Liu S; Shan Z; Jiang C; Tian Y; Jin Z
Int J Clin Exp Pathol; 2014; 7(12):8715-23. PubMed ID: 25674237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
